Aeromics and Simcere Announce the First-In-Human Dosing of Chinese Healthy Volunteers in Simcere’s Phase I Study of The SIM0307 (AER-271), A New Drug for Brain EdemaDec 9, 2021
NEW HAVEN, Conn. and NANJING, China, Dec. 9, 2021 /PRNewswire/ — Simcere Pharmaceutical Group and Aeromics, Inc. today announced that Simcere dosed the first subjects in the SIM0307 (AER-271) Phase I study conducted in Beijing Tiantan Hospital.
This single-center, randomized, double-blind, placebo-controlled phase I clinical study plans to enroll 56 subjects to evaluate tolerability, safety and pharmacokinetic characteristics after single/multiple administration in healthy Chinese volunteers. Professor Wang Yongjun, Dean of Beijing Tiantan Hospital, Capital Medical University is the principal investigator. The study was officially launched on December 2nd, 2021, with the first dose of 4 subjects in the first dosing group completed on the 8th of December.